drugset / Trial / NCT05807893
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases
Timeline
- Start
- 2023-05-14
- Primary completion
- 2024-03-22
- Completion
- 2024-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | — |